Damora Therapeutics, Inc. - Common Stock (DMRA)

CUSIP: 36322Q206

Q3 2026 13F Holders as of 30 Sep 2026

Security type / class
Equity / Common Stock
Total 13F shares
140
Total 13F value
$2,979
Holder snapshot 6 signals
Share change
-1,059,015
SEC-reported price per share
$21.28
Number of holders
1
Value change
-$27,548,186
Number of buys
1
Number of sells
8
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
61,638,745

Security key

36322Q206

Report period

Q3 2026

Institutions

1

Top holders

1

DMRA full security history Ownership snapshot Full 13F holder table Previous quarter: Q2 2026 Damora Therapeutics, Inc. SEC filings Damora Therapeutics, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of DMRA - Damora Therapeutics, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Fairmount Funds Managemen...
Disclosed value leader
FMR LLC
Comparable rows
9/15
Latest evidence
30 Jun 2026
13F 13D/G 3/4/5 Lead comparable stake: 20% 6 rows are not safely comparable across share classes. 13D/G row: Fairmount Funds Management LLC Showing 1-6 of 15 holder rows.

Quick read

Fairmount Funds Management LLC leads the comparable SEC ownership view at 20%.

9 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Fairmount Funds Management LLC's linked filing trail.
Comparable ownership Top 5
Fairmount Funds Management LLC 20%
FMR LLC 15%
Avoro Capital Advisors LLC 6.3%
Venrock Healthcare Capital Partne... 6%
BlackRock, Inc. 5.1%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Fairmount Funds Management LLC
13F 13D/G 3/4/5
Company · Director, 10%+ Owner
13F 13D/G 3/4/5
20%
Reported 13D/G · 09 Feb 2026
$226,625,130
8,713,000 shares
 — 30 Jun 2026
FMR LLC
13F 13D/G
Company
13F 13D/G
15%
Reported 13D/G · 28 Nov 2025
$240,149,784
9,232,979 shares
 — 30 Jun 2026
Avoro Capital Advisors LLC
13F 13D/G
Company
13F 13D/G
6.3%
Reported 13D/G · 31 Mar 2026
$98,395,830
3,783,000 shares
 — 30 Jun 2026
Venrock Healthcare Capital Partners III, L.P.
13D/G
13D/G
6%
Reported 13D/G · 09 Feb 2026
$78,630,443
3,603,595 shares
 $0 09 Feb 2026
BlackRock, Inc.
13F 13D/G
Company
13F 13D/G
5.1%
Reported 13D/G · 30 Jun 2026
$82,245,389
3,162,068 shares
 — 30 Jun 2026
Paragon Therapeutics, Inc.
13D/G
13D/G
3.4%
Reported 13D/G · 09 Feb 2026
—
2,045,473 shares
 $0 09 Feb 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
1
Shares
140
Rows available
1
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q3 2026 vs Q2 2026 Across Filers

Q2 2026 holders
101
Q3 2026 holders
1
Holder diff
-100
Investor Q2 2026 Shares Q3 2026 Shares Share Diff Share Chg % Q2 2026 value Q3 2026 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .